Nicotine - COVID / SARS / ARDS: Difference between revisions
(Created New Page) |
(Added content) |
||
Line 16: | Line 16: | ||
=Suggested studies to add to this page= | =Suggested studies to add to this page= | ||
===2021: [https://academic.oup.com/ntr/advance-article/doi/10.1093/ntr/ntab004/6073671?fbclid=IwAR3PlyqgttsQh0MO7f6T8EYcGXt6Rd5GXF303SFe-hPQpsGl_wzaho04djs Impact of Tobacco Smoking on the risk of COVID-19.A large scale retrospective cohort study]=== | |||
=Threads about COVID on Twitter by @phil_w888= | =Threads about COVID on Twitter by @phil_w888= | ||
==[https://twitter.com/phil_w888/status/1251956936947331072 So far all existing data show smokers are underrepresented in Covid19 hospitalization data]== | |||
===[https://twitter.com/phil_w888/status/1251956936947331072 So far all existing data show smokers are underrepresented in Covid19 hospitalization data]=== | |||
*[https://threadreaderapp.com/thread/1251956936947331072.html Above thread on threadreader app] | *[https://threadreaderapp.com/thread/1251956936947331072.html Above thread on threadreader app] | ||
==[https://twitter.com/phil_w888/status/1279973073811197952 The results of preprints & peer-reviewed studies describing the relationship between smoking and SARS-CoV-2/COVID-19 are reported in this thread]== | |||
===[https://twitter.com/phil_w888/status/1279973073811197952 The results of preprints & peer-reviewed studies describing the relationship between smoking and SARS-CoV-2/COVID-19 are reported in this thread]=== | |||
*[https://threadreaderapp.com/thread/1279973073811197952.html Above thread on threadreader app] | *[https://threadreaderapp.com/thread/1279973073811197952.html Above thread on threadreader app] | ||
==[https://twitter.com/phil_w888/status/1282094429398921216 A compilation of preprints, peer-reviewed studies, and datasets documenting SARS-CoV-2/Covid-19 patients' smoking status - only the ones with at least 1000 patients.]== | |||
==[https://twitter.com/phil_w888/status/1282814318782771200 Studies of SARS-CoV-2/Covid-19 patients in which vaping is mentioned]== | |||
===[https://twitter.com/phil_w888/status/1282094429398921216 A compilation of preprints, peer-reviewed studies, and datasets documenting SARS-CoV-2/Covid-19 patients' smoking status - only the ones with at least 1000 patients.]=== | |||
*Thread on twitter | |||
===[https://twitter.com/phil_w888/status/1282814318782771200 Studies of SARS-CoV-2/Covid-19 patients in which vaping is mentioned]=== | |||
*Thread on twitter | |||
=Nicotine Replacement Therapy (NRT)= | =Nicotine Replacement Therapy (NRT)= | ||
==2020: Nicotine-replacement therapy, as a surrogate of smoking, and the risk of hospitalization with Covid-19 and all-cause mortality: a nationwide, observational cohort study in France== | |||
===2020: Nicotine-replacement therapy, as a surrogate of smoking, and the risk of hospitalization with Covid-19 and all-cause mortality: a nationwide, observational cohort study in France=== | |||
From February 15, 2020 to June 7, 2020, hospitalization with Covid-19 occurred in 647 patients (151 patients in the nicotine-replacement therapy group and 496 patients in the unexposed group). | From February 15, 2020 to June 7, 2020, hospitalization with Covid-19 occurred in 647 patients (151 patients in the nicotine-replacement therapy group and 496 patients in the unexposed group). | ||
Results In the first analysis, 297,070 individuals without major smoking-related diseases exposed to nicotine-replacement therapy were matched with 558,228 unexposed individuals without major smoking-related diseases. | Results In the first analysis, 297,070 individuals without major smoking-related diseases exposed to nicotine-replacement therapy were matched with 558,228 unexposed individuals without major smoking-related diseases. | ||
In the main multivariable analysis, nicotine-replacement therapy was associated with a decreased risk of hospitalization with Covid-19 compared with unexposed individuals. | In the main multivariable analysis, nicotine-replacement therapy was associated with a decreased risk of hospitalization with Covid-19 compared with unexposed individuals. | ||
Nicotine-replacement therapy exposure was also associated with a decreased risk of intubation or death in hospitalized individuals with Covid-19. (13 vs. 73 patients). | Nicotine-replacement therapy exposure was also associated with a decreased risk of intubation or death in hospitalized individuals with Covid-19. (13 vs. 73 patients). | ||
=Smoking= | =Smoking= | ||
==2020: How nicotine can inhibit cytokine storm in the lungs and prevent or lessen the severity of COVID-19 infection?== | |||
===2020: How nicotine can inhibit cytokine storm in the lungs and prevent or lessen the severity of COVID-19 infection?=== | |||
COVID-19 positive patients who smoke are more often asymptomatic or exhibit less severe respiratory symptoms than non-smokers. | COVID-19 positive patients who smoke are more often asymptomatic or exhibit less severe respiratory symptoms than non-smokers. | ||
The macrophages, which are directly infected by the SARS-CoV-2 virus, may drive the cytokine storm in the lings. | The macrophages, which are directly infected by the SARS-CoV-2 virus, may drive the cytokine storm in the lings. | ||
Line 42: | Line 62: | ||
The nicotine use may lessen or eliminate ARDS in the smoking COVID -19 patients. | The nicotine use may lessen or eliminate ARDS in the smoking COVID -19 patients. | ||
==2020: Characteristics and risk factors for COVID-19 diagnosis and adverse outcomes in Mexico: an analysis of 89,756 laboratory–confirmed COVID-19 cases== | |||
===2020: Characteristics and risk factors for COVID-19 diagnosis and adverse outcomes in Mexico: an analysis of 89,756 laboratory–confirmed COVID-19 cases=== | |||
COVID-19 patients were disproportionately older, males and with increased prevalence of one or more comorbidities, particularly diabetes, obesity, and hypertension. | COVID-19 patients were disproportionately older, males and with increased prevalence of one or more comorbidities, particularly diabetes, obesity, and hypertension. | ||
Current smokers were 23% less likely to be diagnosed with COVID-19 compared to non-smokers. | Current smokers were 23% less likely to be diagnosed with COVID-19 compared to non-smokers. | ||
=Smokeless Tobacco= | =Smokeless Tobacco= | ||
=Vapor Technology= | =Vapor Technology= | ||
Revision as of 20:14, 10 January 2021
Studies, Surveys, Papers, and Case Studies
- Sometimes it's necessary to view the PDF version to access the full study.
- This page is for referencing the possible benefits of Nicotine in the battle against COVID / SARS / ARDS.
- If you'd prefer someone else to add a study to a topic, there is a subject section called "Suggested studies to add to this page". You may put the link in that section for one of the regular page editors to address.
- PAGE EDITORS - Please only add Studies, Surveys, Papers in this format to keep page consistent for all viewers.
- Topic
- Year (list new to old) Name of Study (In link format to the study)
- Note here if animal study (leave blank if not)
- Brief Summary
- Link to PDF Version
- Citation
- Acknowledgements (funded by, helped by)
- Keywords
- Other
Suggested studies to add to this page
2021: Impact of Tobacco Smoking on the risk of COVID-19.A large scale retrospective cohort study
Threads about COVID on Twitter by @phil_w888
So far all existing data show smokers are underrepresented in Covid19 hospitalization data
The results of preprints & peer-reviewed studies describing the relationship between smoking and SARS-CoV-2/COVID-19 are reported in this thread
A compilation of preprints, peer-reviewed studies, and datasets documenting SARS-CoV-2/Covid-19 patients' smoking status - only the ones with at least 1000 patients.
- Thread on twitter
Studies of SARS-CoV-2/Covid-19 patients in which vaping is mentioned
- Thread on twitter
Nicotine Replacement Therapy (NRT)
2020: Nicotine-replacement therapy, as a surrogate of smoking, and the risk of hospitalization with Covid-19 and all-cause mortality: a nationwide, observational cohort study in France
From February 15, 2020 to June 7, 2020, hospitalization with Covid-19 occurred in 647 patients (151 patients in the nicotine-replacement therapy group and 496 patients in the unexposed group). Results In the first analysis, 297,070 individuals without major smoking-related diseases exposed to nicotine-replacement therapy were matched with 558,228 unexposed individuals without major smoking-related diseases. In the main multivariable analysis, nicotine-replacement therapy was associated with a decreased risk of hospitalization with Covid-19 compared with unexposed individuals. Nicotine-replacement therapy exposure was also associated with a decreased risk of intubation or death in hospitalized individuals with Covid-19. (13 vs. 73 patients).
Smoking
2020: How nicotine can inhibit cytokine storm in the lungs and prevent or lessen the severity of COVID-19 infection?
COVID-19 positive patients who smoke are more often asymptomatic or exhibit less severe respiratory symptoms than non-smokers. The macrophages, which are directly infected by the SARS-CoV-2 virus, may drive the cytokine storm in the lings. Stimulation of macrophage ACh receptors by nicotine inhibits pro-inflammatory cytokines production and inflammatory response. The nicotine use may lessen or eliminate ARDS in the smoking COVID -19 patients.
2020: Characteristics and risk factors for COVID-19 diagnosis and adverse outcomes in Mexico: an analysis of 89,756 laboratory–confirmed COVID-19 cases
COVID-19 patients were disproportionately older, males and with increased prevalence of one or more comorbidities, particularly diabetes, obesity, and hypertension. Current smokers were 23% less likely to be diagnosed with COVID-19 compared to non-smokers.
Smokeless Tobacco
Vapor Technology
More Information
- Click on the category link below for more studies by topic on Nicotine.